According to Competitive Technologies, Early Breastest, a non-invasive technology, generates an analysis that detects angiogenesis, an early predictor of the possibility of cancer. The agreement provides for sharing of revenue derived from the technology.
John Nano, chairman, president and CEO of Competitive Technologies, said: “The Early Breastest technology is another part of our rapidly developing medical strategy, an example of a Competitive Technologies technology being at the forefront of the paradigm shift to treat individuals with integrative medicine, combining both traditional medicine and holistic medicine.”